ArticleAntimicrobial agents and chemotherapy1997
In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.
Article in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 190 citations in OpenAlex.
- Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.Antimicrobial agents and chemotherapy · 2002Trial
- Targeting fungal lipid synthesis for antifungal drug development and potentiation of contemporary antifungals.npj antimicrobials and resistance · 2025Review
- Mechanism Underlying Conflicting Drug-Drug Interaction Between Aprepitant and Voriconazole via Cytochrome P450 3A4-Mediated Metabolism.Yonago acta medica · 2024Article
- Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review.Clinical pharmacokinetics · 2024Review
- Development and validation of a colorimetric antifungal susceptibility testing method for the dimorphic fungus Talaromyces marneffei.Medical mycology · 2023Article
- Therapeutic drug monitoring andTranslational pediatrics · 2022Article
- Article
- Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic-pharmacodynamic analysis of tear fluid following oral administration.Veterinary ophthalmology · 2020Article
- Management of pulmonaryThe Journal of international medical research · 2020Article
- A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis.Journal of clinical medicine · 2019Article
- Voriconazole-induced periostitis: a new rheumatic disorder.Clinical rheumatology · 2017Review
- Invasive Microascus trigonosporus Species Complex Pulmonary Infection in a Lung Transplant Recipient.Case reports in transplantation · 2015Article
- Mycetoma medical therapy.PLoS neglected tropical diseases · 2014Review
- CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Pharmacotherapy · 2014Review
- Reflections on the approach to treatment of a mycologic disaster.Antimicrobial agents and chemotherapy · 2013Article
- Disseminated amphotericin-resistant fusariosis in acute leukemia patients: report of two cases.Mycopathologia · 2013Article
- Lasiodiplodia theobromae keratitis: a case report and review of literature.Mycopathologia · 2012Review
- Induction of chlamydospore formation in fusarium by cyclic lipopeptide antibiotics from Bacillus subtilis C2.Journal of chemical ecology · 2012Article
- An integrated approach for identification and target validation of antifungal compounds active against Erg11p.Antimicrobial agents and chemotherapy · 2012Article
- Penicillium marneffei Infection in AIDS.Pathology research international · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro activity of voriconazole was compared with that of itraconazole. Eighty-six isolates of pathogenic molds belonging to 23 species were tested by an agar dilution method in High Resolution medium. Voriconazole was more active than itraconazole against a number of hyaline molds, including several Fusarium spp. and Scedosporium prolificans. Voriconazole and itraconazole showed comparable good activity against several hyaline molds, including Penicillium marneffei and Scedosporium apiospermum, and a number of dematiaceous molds, including Bipolaris australiensis, Cladophialophora bantiana, several Exophiala spp., and several Fonsecaea spp. Our results suggest that voriconazole could be effective against a wide range of mold infections in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.